Headlands Technologies LLC Reduces Stake in Integra LifeSciences Holdings Corporation $IART

Headlands Technologies LLC reduced its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 62.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,462 shares of the life sciences company’s stock after selling 36,173 shares during the quarter. Headlands Technologies LLC’s holdings in Integra LifeSciences were worth $385,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $25,000. Osaic Holdings Inc. increased its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in Integra LifeSciences during the 2nd quarter valued at $82,000. Tower Research Capital LLC TRC raised its holdings in Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares during the period. Finally, Virtu Financial LLC bought a new stake in Integra LifeSciences in the fourth quarter worth $124,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. Citigroup restated a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Truist Financial lifted their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Finally, UBS Group started coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $18.86.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $16.44 on Friday. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The stock’s fifty day moving average is $17.84 and its two-hundred day moving average is $14.43. Integra LifeSciences Holdings Corporation has a 52 week low of $8.70 and a 52 week high of $20.49. The company has a market capitalization of $1.28 billion, a PE ratio of -182.65, a price-to-earnings-growth ratio of 0.86 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, analysts expect that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.